Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip. by Atianzar, Kimberly et al.
Providence St. Joseph Health
Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
2-1-2019
Why Did COAPT Win While MITRA-FR Failed?
Defining the Appropriate Patient Population for
MitraClip.
Kimberly Atianzar
Swedish Heart and Vascular Institute Seattle, WA, US.
Ming Zhang
Swedish Medical Center, Seattle, Washington
Zachary Newhart
Swedish Heart and Vascular Institute Seattle, WA, US.
Sameer Gafoor
Swedish Heart and Vascular, Seattle, WA, USA.
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Cardiology Commons
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles,
Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact
digitalcommons@providence.org.
Recommended Citation
Atianzar, Kimberly; Zhang, Ming; Newhart, Zachary; and Gafoor, Sameer, "Why Did COAPT Win While MITRA-FR Failed?
Defining the Appropriate Patient Population for MitraClip." (2019). Articles, Abstracts, and Reports. 1318.
https://digitalcommons.psjhealth.org/publications/1318
45©  R A D C L I F F E  C A R D I O L O G Y  2 0 1 9
Structural
Access at: www.ICRjournal.com
In patients with heart failure and reduced left ventricular ejection 
fraction (LVEF), secondary (functional) mitral regurgitation, in which 
the mitral valve leaflets and chordae are essentially normal, is the 
result of functional and structural alterations of the left ventricle 
(LV). Severe secondary mitral regurgitation (MR) is a predictor of 
poor clinical outcomes in this patient population due to more 
hospitalisations for heart failure (HF), poor quality of life and 
shortened survival times.1–4 While guideline-directed medical therapy 
(GDMT) may have an impact on LV function, symptomatology and 
functional MR severity, there has been no data to show that surgical 
treatment of secondary MR is associated with lower incidence of 
death or hospitalisation.5
Percutaneous transcatheter treatment can be used to reduce MR 
where the anterior and posterior mitral valve leaflets are approximated 
with the MitraClip device (Abbott Vascular). In the Endovascular Valve 
Edge-to-Edge Repair Study II (EVEREST II) trial, Feldman et al. showed 
that although the MitraClip was safer than surgical mitral valve repair, 
the transcatheter option was not as effective in reducing MR severity 
among the study group, who mostly had primary MR.6 Prospective 
clinical trials with hard clinical outcomes on the beneficial effect on 
secondary MR of enhancing GDMT with percutaneous transcatheter 
mitral valve repair had not been shown until now.7 
At the 2018 Transcatheter Cardiovascular Therapies 30th Scientific 
Session Conference, Gregg Stone presented the long-awaited and 
ground-breaking results of the Cardiovascular Outcomes Assessment 
of the MitraClip Percutaneous Therapy for Heart Failure Patients 
with Functional Mitral Regurgitation (COAPT) randomised prospective 
clinical trial. COAPT showed that in more than 600 patients with heart 
failure and severe functional MR, transcatheter percutaneous mitral 
valve repair using the MitraClip device in conjunction with GDMT 
when compared with GDMT alone, not only significantly reduced the 
primary endpoint of heart failure rehospitalisations by 47%, but also 
mortality at two years by 38%.7 Additionally, all 10 secondary endpoints 
met statistical significance in favour of the MitraClip with GDMT over 
GDMT alone. The reaction of the audience when the primary endpoint 
results slide was displayed on the screen was enormous, with an 
audible gasp followed by cheering and clapping. It had been difficult to 
imagine the clinical outcome of the COAPT trial due to slow enrolment, 
a lengthy time to complete, but mostly due to ominous predictions 
in light of the outcomes from the Multicentre Study of Percutaneous 
Mitral Valve Repair MitraClip Device in Patients With Severe Secondary 
Mitral Regurgitation (MITRA-FR) clinical trial.  
The COAPT trial results were clearly different from the negative results 
of the MITRA-FR randomised prospective clinical trial presented by 
Jean François Obadia a month earlier at the 2018 European Society of 
Cardiology Congress.8 In the MITRA-FR trial, more than 300 HF patients 
with severe MR were randomised to be treated with medical treatment 
alone or with percutaneous transcatheter mitral valve repair (MitraClip) 
along with medical therapy. All the participants were evaluated for a 
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primary clinical endpoint at 12 months of a composite of death from 
any cause or unplanned hospitalisation for HF.8 Dr Obadia discussed 
the MITRA-FR trial’s negative primary outcome results at 12 months, 
showing no significant difference in the rate of death or unplanned HF 
hospitalisations in the intervention and control groups (54.6% versus 
51.3%, OR 1.16, 95% CI [0.73 to 1.84], p=0.53).8 
The big question was why there was such a significant difference in the 
results between the MITRA-FR trial and the COAPT trial. Why was the 
COAPT trial successful where the MITRA-FR trial seems to have failed? 
There has been much debate about this issue in the cardiovascular 
world since the two trials were presented. 
A Tale of Two Trials
Recruitment
What is evident is that there were clear differences between the two 
trials regarding patient selection, medical treatment optimisation, 
the severity parameters of MR and the setting of the LV volume 
index parameters. Some of this is due to differences between 
European and American guidelines. In addition, these differences 
were only found in a post-hoc analysis and are therefore subject to 
inherent limitations. 
Nevertheless, in the MITRA-FR trial, the majority of patients had an 
average effective regurgitant orifice area (EROA) of 30 mm2 which 
suggests moderate MR rather than severe, whereas in the COAPT 
trial, the majority of patients had an average EROA of 40 mm2 which is 
truly severe MR. The only COAPT subgroup that did not benefit from 
MitraClip with GDMT was the patients who had an EROA <30 mm2 
in setting of a dilated LV (>96 ml/m2). A significant number of 
patients (52%) with moderate MR (EROA <30 mm2) were enrolled 
in the MITRA-FR trial, whereas only 14% of patients with this 
parameter were enrolled in the COAPT trial. This suggests that the 
MitraClip procedure added to medical therapy optimisation does 
not seem to have a significant beneficial effect on patients with 
moderate MR and dilated LV cardiomyopathy. 
The patient recruitment process was more selective in the COAPT 
trial compared with the MITRA-FR trial, as indicated by the slow 
enrolment and length of time of the trial. One review article 
describes the difference as proportionate mitral regurgitation 
(MITRA-FR) and disproportionate mitral regurgitation (COAPT) to the 
degree of LV dilatation, with the COAPT trial enrolling patients with 
EROA about 30% higher and LV volumes about 30% smaller than the 
MITRA-FR trial.9
Medical Therapy and Optimisation
The ‘guideline-directed’ medical therapy used in the two trials 
differed significantly. The COAPT patients were under more strict 
evaluation with HF specialists overseeing the maximal doses 
tolerated for all medications, before and at the time of the MitraClip 
intervention. Several critiques of the COAPT trial have pointed out 
that even at the highest enrolment centre, Cedars-Sinai Medical 
Center in Los Angeles, with 46 enrolled patients total, that would 
average about one study patient per month receiving the MitraClip 
intervention. Only about 1–12% of patients had medication changes 
during the trial. 
The highly stringent patient selectivity in the COAPT trial is the obvious 
difference between the two trials. The MITRA-FR trial was designed 
to be more true to life in terms of medical therapy and optimisation. 
The rates of drug use and medication titration throughout the MITRA-
FR trial course were not tracked, and although these were guideline 
directed, they may not have been guideline optimised. 
Yet the story does not end here – the percentage of drugs used in 
MITRA-FR was higher than COAPT even if dose optimisation was not 
checked by a selection committee. In addition, although there were 
a significant number of HF hospitalisations in the COAPT trial, the 
doses of medications were not changed significantly. 
Size of Study and Study Design
The number of patients and follow-up were different between the two 
trials. The MITRA-FR trial enrolled about 300 patients, 150 in each arm; 
and the COAPT trial enrolled about 600, 300 in each arm. Perhaps 
an effect size may not have been seen in MITRA-FR that was seen 
in COAPT. Although hospitalisations differed early on between the 
two patient groups in the COAPT trial (partly due to a more rigorous 
medical arm), mortality did not differentiate until the second year. The 
follow-up period for MITRA-FR was only 1 year. Perhaps the positive 
nature of COAPT could be partially down to better design, probably due 
to more accessible funding.
Technical Success and Procedural Safety
Technical success and procedural safety may be different between 
the two trials. Residual MR class ≥3+ was higher post-clip for MITRA-
FR compared with COAPT, both acutely (9% versus 5%) and at 12 
months (17% versus 5%); procedural complications – although low 
and improving with current experience – were higher in MITRA-FR 
than in COAPT (14.6% versus 8.5%), and residual MR class ≥3+ was 
higher post-clip for MITRA-FR compared with COAPT, both acutely 
(9% versus 5%) and at 12 months (17% versus 5%).7–8 
It is important to note that there was no common core lab evaluation 
of both trials. More patients in COAPT had more than one clip 
implanted compared with patients in the MITRA-FR trial. This raises 
questions over the use of 3D imaging during the procedure. 3D 
imaging is better than 2D imaging at identifying location of jets, 
perpendicularity, post-clip leak and mitral valve area. For procedural 
complications, there was about a twofold higher rate of device 
implant failure, cardiogenic shock, stroke and tamponade in MITRA-
FR compared with COAPT, which may be due to different patient 
populations or patients who are at different stages of the disease. 
These are significant issues that are likely to be associated with 
negative primary outcomes.
Selecting Patients Who Will Benefit From MitraClip 
Overall, how did the COAPT and MITRA-FR trials help in selecting the 
most appropriate patient with secondary (functional) MR to receive 
MitraClip therapy? The COAPT trial shows us that patients have to be 
symptomatic, have substantial MR and have LV dysfunction (but not 
too much dysfunction) and be on the highest tolerated doses of HF 
medications. Patient selection, medical management and procedural 
timing is key for success. This means that HF physicians will need 
to be involved (and incentivised) members of the evaluation and 
management team for mitral valve disease. Periprocedural imaging 
and procedural technique needs to be optimised and patients with 
only one clip should be evaluated closely. Patients with at least a 
2-year expected lifespan after the procedure may do better from 
a mortality standpoint, which should be part of the initial screening. 
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The Future
There are still some unanswered questions from these trials. Some 
of these are based on COAPT subsets to better identify patients who 
will benefit from the intervention, such as effects based on patients 
with or without frailty, medical changes during the trial period, 
postprocedural high gradient and more. 
How do we improve the medical and procedural treatment for 
those in MITRA-FR who are outside the range of COAPT? Will 
other therapies,such as rings and valve replacement, provide better 
outcomes, and for which patients? These are questions worthy of 
consideration and we will undoubtedly see more data in the coming 
years. At this time, both trials provide guidance we may use to get 
maximal results in practice, and create opportunities for other mitral 
valve therapies to also work in the COAPT and MITRA-FR patient 
spaces. It is important to remember that MR and HF are a vast frontier 
for us to explore and these two trials are just the beginning. We have 
neither won nor lost at this time – we are still gathering information 
about this important disease process, and our patients will look to us 
for answers in the years ahead. 
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